- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04434976
Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China
Study Overview
Status
Detailed Description
This research is a retrospective, multicenter, case-control study. The purpose of this study is to collect and assess health-seeking pathways, sociodemographic characteristics and symptoms of 400 newly diagnosed patients with bacteriologically confirmed pulmonary tuberculosis(TB).
According to inclusion criteria and exclusion criteria, a total of 400 participants with bacteriologically confirmed TB will be recruited and acquired their health-seeking pathways in different clinical institutions of pulmonary tuberculosis. Totally, 20 TB-designated medical institutions will be conducted in depth, covering the eastern region (7), the central region (8) and the western region (5), each hospital will enroll 20 eligible patients on the basis of convenience.
The cohorts are divided into delayed diagnosis and undelayed diagnosis. The former is defined if The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert. By offline or online interview, we aim to collect basic sociodemographic characteristics, symptoms, health-seeking pathway, including: hospital name, the date of each visit, laboratory tests and radiology evaluation results, diagnosis, treatment, medical and transportation costs. Then list the hospitals of previous consultations and trace their classification through the official website of the Health and Medical Commission. Determine whether these hospital are designated institution based on the CDC's publicity. Consult the laboratory facilities by phone.
The primary objective is to gain the median time of pulmonary tuberculosis diagnosis confirmed and the correlation between the classification of the first-visit-institution and the diagnosis delay of the pulmonary tuberculosis.
The secondary objective is to gain the bacteriology examination coverage rate: anti fast bacteria smear, tuberculosis culture, and GeneXpert; the correlation between the use of fluoroquinolones as anti-infection treatment before tuberculosis diagnosis confirmed and the diagnosis delay of the pulmonary tuberculosis; the sociodemographic characteristics of patients with or without pulmonary tuberculosis diagnosis delay; The rates of onset symptoms and its correlation to diagnosis delayed of pulmonary tuberculosis diagnosis confirmed patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China
- Anhui Province Hospital
-
-
Guangdong
-
Shenzhen, Guangdong, China
- The Third People's Hospital of Shenzhen
-
-
Guangxi
-
Beihai, Guangxi, China
- Beihai Tuberculosis Hospital
-
-
Guizhou
-
Guiyang, Guizhou, China
- Guiyang Public Health Clinical Center
-
-
Hei Longjiang
-
Daqing, Hei Longjiang, China
- The 2th Hospital of Daqing
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Province Infectious Diseases Hospital
-
-
Hubei
-
Wuhan, Hubei, China
- Wuhan Medical Treatment Center
-
-
Hunan
-
Huaihua, Hunan, China
- The First People's Hospital of Huaihua
-
-
Jiangsu
-
Taicang, Jiangsu, China
- The First People's Hospital of Taicang
-
Xuzhou, Jiangsu, China
- Xuzhou Infectious Diseases Hospital Huimei Liu
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- Jiangxi Province Chest Hospital
-
-
Jilin
-
Changchun, Jilin, China
- Changchun Infectious Diseases Hospital
-
-
Shandong
-
Jinan, Shandong, China
- Shandong Province Chest hospital
-
-
Shanghai
-
Shanghai, Shanghai, China
- Shanghai Public Health Clinical Center
-
Shanghai, Shanghai, China
- 905th Hospital of PLA Navy
-
-
Shanxi
-
Xian, Shanxi, China
- Xian Chest Hospital
-
-
Sichuan
-
Luzhou, Sichuan, China
- Southwest Medical University Affiliated Hospital
-
-
Yunnan
-
Qiubei, Yunnan, China
- Qiubei People's Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Hangzhou Red Cross Hospital
-
Wenzhou, Zhejiang, China
- Wenzhou Central Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Bacteriological positive: including positive AFB smear/ culture / molecular test;
- Agree to accept this survey;
Exclusion Criteria:
- HIV antibody positive and AIDS patients;
- Combined with extrapulmonary TB;
- Critically ill patients, and according to the judgment of the research physician, it is impossible to survive for more than 16 weeks;
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
delayed diagnosis
The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days.
Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
|
undelayed diagnosis
The length from the first clinical visit date to the diagnosis confirmed date is equal or less than 14 days.
Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The median time of pulmonary tuberculosis diagnosis confirmed
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
|
Time from the date of patients' symptoms onset to the date of pulmonary tuberculosis diagnosis confirmed
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
The correlation between the classification of the first-visit-institution and the diagnosis delay of the pulmonary tuberculosis
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
|
We collect the classification and the quality of the first-visit-institution of diagnosis confirmed patients by asking the past medical histories.
According to the evidence of duration from symptoms onset to pulmonary TB diagnosis confirmed, use logistic correlation to find the relation between the classification of the first-visit-institution and the diagnosis delay.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bacteriology examination coverage rate: anti fast bacteria smear, tuberculosis culture, and GeneXpert.
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
|
According to the patients' health-seeking pathways, calculate the test coverage rates including anti fast bacteria smear, tuberculosis culture, and GeneXpert in different clinical institutions.
The test coverage rates is acquired by recording the laboratory test reports in medical systems or paper version from patients.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
The correlation between the use of fluoroquinolones as anti-infection treatment before tuberculosis diagnosis confirmed and the diagnosis delay of the pulmonary tuberculosis
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
|
We collect the fluoroquinolones use evidence of each patients in different clinical institutions by asking the past medical histories and reviewing paper reports from patients as well as medical system.
Then use logistic correlation to find the relation between the fluoroquinolones use history and the diagnosis delay of the pulmonary tuberculosis.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
The sociodemographic characteristics of patients with or without pulmonary tuberculosis diagnosis delay.
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
|
Calculating the distribution of patients' sociodemographic characteristics and correlation between results above and pulmonary tuberculosis diagnosis delay.
Patients' sociodemographic characteristics includes: age, sex, marriage status, nation, occupation, education status, annual family income per capita, underlying disease such as diabetes, habits of smoking and habits of drinking alcohol.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
The rates of onset symptoms and its correlation to diagnosis delayed of pulmonary tuberculosis diagnosis confirmed patients.
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
|
According to the past medical history of each pulmonary tuberculosis diagnosis confirmed patients, we collect their onset symptoms and calculate the rate respectively.
Then use logistic correlation to find the relation between the onset symptoms and the diagnosis delay of the pulmonary tuberculosis.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wenhong Zhang, PHD, Huashan Hospita
Publications and helpful links
General Publications
- Liu R, Li J, Tan Y, Shang Y, Li Y, Su B, Shu W, Pang Y, Gao M, Ma L. Multicenter evaluation of the acid-fast bacillus smear, mycobacterial culture, Xpert MTB/RIF assay, and adenosine deaminase for the diagnosis of tuberculous peritonitis in China. Int J Infect Dis. 2020 Jan;90:119-124. doi: 10.1016/j.ijid.2019.10.036. Epub 2019 Nov 4.
- Martinez L, Xu L, Chen C, Sekandi JN, Zhu Y, Zhang C, Whalen CC, Zhu L. Delays and Pathways to Final Tuberculosis Diagnosis in Patients from a Referral Hospital in Urban China. Am J Trop Med Hyg. 2017 May;96(5):1060-1065. doi: 10.4269/ajtmh.16-0358. Epub 2017 Feb 13.
- Hogan CA, Puri L, Gore G, Pai M. Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: A systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis. 2016 Dec 13;6:1-7. doi: 10.1016/j.jctube.2016.12.001. eCollection 2017 Jan.
- Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008 Jan 14;8:15. doi: 10.1186/1471-2458-8-15.
- Hanson CL, Osberg M, Brown J, Durham G, Chin DP. Conducting Patient-Pathway Analysis to Inform Programming of Tuberculosis Services: Methods. J Infect Dis. 2017 Nov 6;216(suppl_7):S679-S685. doi: 10.1093/infdis/jix387.
- Hanson C, Osberg M, Brown J, Durham G, Chin DP. Finding the Missing Patients With Tuberculosis: Lessons Learned From Patient-Pathway Analyses in 5 Countries. J Infect Dis. 2017 Nov 6;216(suppl_7):S686-S695. doi: 10.1093/infdis/jix388.
- Farhat MR, Jacobson KR, Franke MF, Kaur D, Murray M, Mitnick CD. Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clin Infect Dis. 2017 Oct 15;65(8):1364-1370. doi: 10.1093/cid/cix556.
- Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan 15;64(2):111-115. doi: 10.1093/cid/ciw778.
- GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. Lancet Infect Dis. 2018 Dec;18(12):1329-1349. doi: 10.1016/S1473-3099(18)30625-X.
- Mijiti P, Yuehua L, Feng X, Milligan PJ, Merle C, Gang W, Nianqiang L, Upur H. Prevalence of pulmonary tuberculosis in western China in 2010-11: a population-based, cross-sectional survey. Lancet Glob Health. 2016 Jul;4(7):e485-94. doi: 10.1016/S2214-109X(16)30074-2. Epub 2016 Jun 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY-2019TB-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis; Pulmonary, Confirmed, Unspecified Means
-
Duke UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingUnspecified Child Maltreatment, Suspected | Unspecified Child Maltreatment, ConfirmedUnited States
-
Duke UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingUnspecified Child Maltreatment, Suspected | Unspecified Child Maltreatment, ConfirmedUnited States
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Tjip van der WerfGadjah Mada University; The Enose Company, Zutphen the NetherlandsCompletedPulmonary Tuberculosis Suspected | Other Specified Chronic Obstructive Pulmonary Disease | Pulmonary Tuberculosis TB (+) Histology, (-) BacteriologyIndonesia
-
Research Institute of Epidemiology, Microbiology...Active, not recruitingAspergillosis | Pulmonary Tuberculoses | Old Tuberculosis | Active Tuberculosis | Chronic Pulmonary AspergillosisUzbekistan
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University of Liverpool; Ministry... and other collaboratorsRecruitingMulti-drug Resistant Tuberculosis | Pulmonary Tuberculoses | Extensively Drug-Resistant TuberculosisBelarus, South Africa, Uzbekistan
-
Northwell HealthCompletedPostpartum Depression | Unspecified Child Maltreatment, Suspected | Unspecified Child Maltreatment, ConfirmedUnited States
-
Michael HoelscherRadboud University Medical Center; German Federal Ministry of Education and... and other collaboratorsCompletedPulmonary Tuberculoses | Other Specified Pulmonary TuberculosisSouth Africa
-
Radboud University Medical CenterEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Department... and other collaboratorsCompletedPulmonary Tuberculosis (TB)South Africa